Analytical Method Validation for Biopharmaceuticals: A Practical Guide - - BioPharm International

ADVERTISEMENT

Analytical Method Validation for Biopharmaceuticals: A Practical Guide


BioPharm International




Analytical method validation (AMV) is required in the biopharmaceutical industry for all methods used to test final containers (release and stability testing), raw materials, in-process materials, and excipients. 1 AMV is also required for test methods that are used to validate the process prior to process validation. This article reviews current regulatory guidelines and the critical elements of analytical method development (AMD) that should be finalized before starting AMV.

Regulatory Guidelines Analytical methods are non-microbiological procedures which are used to test final containers, raw materials, in-process materials, and excipients for release or to determine stability. Guidance for microbiological test method validation is reviewed in the Parenteral Drug Association (PDA) Technical Report No. 33 and is outside of the scope of this guide.2 The International Conference on Harmonisation (ICH)'s Q2A and Q2B and the United States Pharmacopoeia's USP 28 <1225> provide basic guidance.3-5 However, following just these guidelines may not provide sufficient evidence that a method is suitable for product release.6,7 FDA provides guidance on some of the issues that are not currently covered elsewhere.8,9

In addition to compliance, a biopharmaceutical manufacturer must consider how the acceptance criteria for the process validation and all corresponding test methods are connected to the statistically derived product specifications that support acceptable product release-to-reject ratios.6,7 This article addresses three major deficiencies in the available guidelines:

  • the lack of clear expectations concerning when to qualify, validate, and verify test methods
  • the lack of clear expectations concerning when certain method performance aspects should be covered (AMD or AMV)
  • the lack of guidance for setting AMV acceptance criteria that directly impact product specifications and predicted product release-to-reject ratios, which could ultimately impact patients and firms.

Qualify, Validate, or Verify? The US Code of Federal Regulation 21 CFR 211.194(a)(2)) does not require recognized standard reference methods that have already been validated and published in a standard reference (such as USP 28) to be fully revalidated.1,5 However, a biopharmaceutical firm must verify the suitability of these validated and published methods for their specific product and laboratory environment.5 The verification of the suitability of methods under actual conditions of use is acceptable in the following cases:
  • the methods are published in the current revision of the USP
  • the methods are published in the Association of Official Analytical Chemists (AOAC) Book of Methods or another recognized standard reference
  • the methods are detailed in an approved new drug application and the referenced method is not modified.1


Table 1: Applicability and Requirements for Analytical Method Qualification, Validation, and Verification
In addition to the validation of new methods and the verification of previously validated methods, there is a third category, analytical method qualification (AMQ), which can be used under appropriate circumstances. However, before AMQ can be used, the exact scope or applicability and the detailed definitions for all three AMV categories must appear in a firm's written procedures. Table 1 summarizes the general expectations for the applicability and requirements for using one of these three validation strategies.10-12


Table 2: Validation Characteristics Per ICH Q2A and Q2B
Which Performance Criteria? The final AMV document must include evidence that a particular test procedure is suitable for its intended use. Formal method validation studies should include all relevant ICH Q2A/B AMV characteristics listed in Table 2. The AMV protocol includes all scientifically justified and logical step-by-step validation studies. Whenever a test method is developed and will be used for drug development from Phase IIb onward, material for lot release, raw materials, in-process, or excipients, the AMD studies should contain a series of critical elements. The evaluation of AMD characteristics should precede AMV and should be summarized in an AMD report.6,7 All AMD data should ideally be generated in a GLP/GMP environment using qualified equipment operated by qualified personnel, properly documented, summarized in an AMD report, and approved by quality assurance (QA). These results can be used as a qualified method for material tested before Phase IIb.10 This also ensures that all AMD/AMQ data and results (summarized later in the AMV protocol) are valid from a compliance perspective. Critical method performance criteria that should be evaluated during AMD are described below. The main argument for evaluating these criteria during the AMD phase is to ensure that a test system is truly optimized before AMV. The validation process should not be a trial-and-error effort but rather a formal process demonstrating that all AMV acceptance criteria are readily met.




AMV Characteristics Assay performance criteria such as accuracy and specificity are defined for analytical methods in current guidelines and should always be covered during AMV according to assay classification.3,4 The validation characteristics for each test method category are listed in Table 2 and briefly described below. The five ICH Q2A/B test categories are listed across the top row of Table 2, and the corresponding product specifications which would trigger the selection of one of these five categories are listed in the second row. For example, a test that reports levels of a characterized impurity should be validated as a quantitative limit test, and the AMV should include a formal evaluation of a total of seven characteristics.12,13 On the other hand, a qualitative limit test for an impurity will have product specifications reported as less than a particular pre-set limit. The actual impurity concentrations are not reported; only the detection limit (DL) and specificity are required AMV characteristics. We are not quantitatively reporting this result, so we are not required to evaluate the quantitative method characteristics.

Accuracy is usually demonstrated by spiking an accepted reference standard into the product matrix. Percent recovery (observed/expected x 100%) should ideally be demonstrated over the entire assay range using multiple data points for each selected analyte concentration. Demonstrating accuracy is mostly affected by how well the reference standard is characterized and how well systematic sample preparation errors are controlled. Data generated for determining accuracy may be used for other validation characteristics, such as repeatability precision, linearity, assay range, and quantitation limit.

Repeatability precision indicates how precise the test results are under ideal conditions (same sample, operator, instrument, and day). Repeatability precision should be demonstrated over the entire assay range, as with accuracy. Accuracy data may be used.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

EMA Warns of Falsified Herceptin Vials
April 16, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Author Guidelines
Source: BioPharm International,
Click here